Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) can affect sleep for some people, though the picture is more nuanced than a simple yes or no. Changes in sleep quality are reported by a minority of people taking the medicine, and the causes are usually traceable to specific, manageable factors rather than a direct sedative or stimulant effect. As with all prescription-only weight-loss medicines, suitability is a clinical decision, not something you can determine from a symptom list alone. Here is what the current evidence and NHS guidance actually say.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A lot of people searching this question have read somewhere that Wegovy causes insomnia, full stop. That framing overstates it. The official patient information leaflet for semaglutide, which you can review in detail via the NHS semaglutide medicines page, lists the side-effect profile in frequency tiers. Sleep disturbance does not sit in the very common or common categories alongside nausea or diarrhoea. What does happen, for a meaningful minority of people, is that other side effects disrupt sleep as a knock-on effect. That is a different problem with different solutions.
The distinction matters because treating "Wegovy causes insomnia" as a fixed fact can make people reluctant to start, or to continue, a treatment that is producing real clinical benefit. Most sleep-related complaints settle as the body adjusts or as the dose finds its level with good prescriber support.
That said, if you want a thorough look at how semaglutide interacts with sleep, our dedicated page exploring whether semaglutide affects sleep covers the evidence in full rather than offering a reassuring brush-off.
The GI side-effect profile of semaglutide is the most plausible culprit for most sleep complaints. Nausea, reflux and stomach discomfort are most pronounced in the hours after an injection and typically peak in the first few days after a dose increase. If you inject in the evening, those sensations may land exactly when you are trying to fall asleep. Switching the injection to the morning is one practical step some people find genuinely useful, though any change to timing should be discussed with your prescriber first.
There is also a smaller group of people who report unusually vivid or intense dreams on GLP-1 receptor agonists, including semaglutide. The mechanism is not fully established. The leading hypothesis involves the way these medicines interact with appetite-regulating centres in the brain, since GLP-1 receptors are not confined to the gut. For most people this is more curious than distressing, and it tends to ease with time.
Fatigue is listed as a common side effect of Wegovy, and disrupted fatigue patterns across the day can knock night-time sleep off-rhythm. Staying well hydrated and eating regular, protein-sufficient meals (even when appetite is reduced) supports more stable energy. Our overview of Wegovy's early effects covers what tends to shift in the first weeks of treatment.
Here is the side of the story that gets far less coverage. Obstructive sleep apnoea (a condition in which the airway repeatedly narrows during sleep, causing broken, unrefreshing nights) is strongly associated with excess body weight, and it qualifies as a weight-related condition under semaglutide's UK licence. As body weight falls on treatment, the structural factors that worsen sleep apnoea often improve too.
The NICE appraisal of semaglutide, published as TA875, explicitly recognises obstructive sleep apnoea as one of the weight-related comorbidities that informs eligibility for treatment on the NHS. That framing reflects a broader clinical view: for people carrying weight that is actively worsening their sleep, semaglutide is more likely to improve sleep over the medium term than to harm it.
People who notice improved sleep quality after several months on Wegovy are not imagining it. Reduced body weight lightens the mechanical load on the airway, and the general metabolic improvements that accompany significant weight loss, including better blood sugar regulation, can translate into more restorative sleep patterns. You can read more about what semaglutide treatment involves on our semaglutide information page.
If sleep changes do occur, a few practical adjustments are worth trying before concluding the medicine is to blame. Shifting your injection day timing so the peak nausea window falls during waking hours is the first lever. Eating a smaller, lower-fat meal before bed reduces the likelihood of reflux disturbing sleep. Keeping the room cool and limiting caffeine from mid-afternoon is basic sleep hygiene that supports the body while it adapts.
Persistent, severe sleep disruption is worth raising directly with your clinical team. The same applies to any mood changes, since low mood or anxiety affecting sleep should always be discussed with a prescriber rather than managed alone. If you are noticing other unexpected physical changes alongside disrupted sleep, that conversation becomes more urgent.
There is also a broader question of whether Wegovy suits you at this point in time. People with significant untreated sleep disorders may find their clinical picture more complex than a straight eligibility check covers. That is exactly the kind of nuance a qualified prescriber works through with you. For a sense of what other physical changes people ask about, hormonal effects are another frequently searched topic. Questions about the medicine's full profile are also covered on the Wegovy overview page.
If you are ready to find out whether treatment is right for you, start your free consultation with our prescribers and get a same-day clinical review.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.